Table 1 Delphi questionnaire consensus report

1

I feel that to implement an antiangiogenic therapy is important to know the infiltration of the tumour into adjacent structures such as:

i. Pleura

0.00

ii. Chest wall

0.00

iii. Bone

0.00

iv. Bronchi

83.33

v. Mediastinum

100.00

vi. Oesophagus

66.67

vii. Trachea

66.67

viii. Carina

83.33

ix. Large vessels

100.00

2

To evaluate vessels infiltration by CT scan in patients with NSCLC, I think it is sufficient to have the resolution given by a thickness of:

i. 5 mm

0.00

ii. 3 mm

83.33

iii. 1.5 mm

83.33

3

In the evaluation of treatment with antiangiogenic therapy I consider essential to know whether or not a thrombus is present

100

4

In the absence of infiltration of vessels, I think that tumour site (central or peripheral) is relevant for treatment

66.67

5

I think that cavitation is a contraindication to antiangiogenic therapy

66.67

6

I believe that the compression of a major vascular structure listed below by a secondary lymphadenopathy is a contraindication for antiangiogenic therapy

i. Vena cava

33.33

ii. Aorta

16.67

iii. Pulmonary arteries

33.33

iv. Pulmonary veins

33.33

7

I think that proximity of the disease to a large vessel is not a contraindication to antiangiogenic therapy

66.67

8

I believe that the alteration of the lung parenchyma may be a risk factor for bleeding if it is:

i. Fibrosis

0.00

ii. Bronchiectasis

50.00

iii. Emphysema

0.00

iv. Endobronchial tumour extension

83.33

v. Pleural effusion

0.00

9

In evaluating the feasibility of antiangiogenic therapy I think it is essential to know the presence of deep venous thrombosis requiring antiplatelet therapy

83.33

10

I think that pleural effusion is always a contraindication to antiangiogenic therapy

0

11

I think that pleural effusion is a contraindication to antiangiogenic therapy only if it is haemorrhagic

50

12

I think pleural effusion is a contraindication to antiangiogenic therapy only after pleurodesis.

0

13

For the chest tumour site, I consider that, to be useful to clinical practice, a structured report should include at least:

i. Cavitation

100.00

ii. Vascular infiltration

100.00

iii. Fistulas

83.33

iv. Endobronchial growth

100.00

v. Lymphangitis

66.67

vi. Margins

83.33

vii. Thromboembolism

100.00

14

For the extrathoracic tumour site, I consider that, to be useful to clinical practice, a structured report should include at least:

i. Fistulas

66.67

ii. Aneurysms

100.00

iii. Diverticula

66.67

iv. Extra-thoracic bleeding sites

100.00

v. Brain metastases

100.00

vi. Thrombi

100.00